Switch to:
Also traded in: Germany, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.22
HCM's Cash-to-Debt is ranked lower than
54% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. HCM: 2.22 )
Ranked among companies with meaningful Cash-to-Debt only.
HCM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64  Med: 1.82 Max: 9.93
Current: 2.22
0.64
9.93
Equity-to-Asset 0.55
HCM's Equity-to-Asset is ranked lower than
62% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. HCM: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
HCM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.54  Med: 0.46 Max: 0.77
Current: 0.55
-0.54
0.77
Piotroski F-Score: 4
Altman Z-Score: 8.53
Beneish M-Score: -2.03
WACC vs ROIC
13.25%
-17.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -10.43
HCM's Operating Margin % is ranked higher than
100% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. HCM: -10.43 )
Ranked among companies with meaningful Operating Margin % only.
HCM' s Operating Margin % Range Over the Past 10 Years
Min: -21.61  Med: -4.82 Max: 58.29
Current: -10.43
-21.61
58.29
Net Margin % 3.77
HCM's Net Margin % is ranked higher than
99% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. HCM: 3.77 )
Ranked among companies with meaningful Net Margin % only.
HCM' s Net Margin % Range Over the Past 10 Years
Min: -26.4  Med: -2.34 Max: 16.27
Current: 3.77
-26.4
16.27
ROE % -17.94
HCM's ROE % is ranked lower than
99% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. HCM: -17.94 )
Ranked among companies with meaningful ROE % only.
HCM' s ROE % Range Over the Past 10 Years
Min: -57.96  Med: -11.5 Max: 9.22
Current: -17.94
-57.96
9.22
ROA % 2.62
HCM's ROA % is ranked lower than
99% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. HCM: 2.62 )
Ranked among companies with meaningful ROA % only.
HCM' s ROA % Range Over the Past 10 Years
Min: -16.75  Med: -1.69 Max: 4.38
Current: 2.62
-16.75
4.38
ROC (Joel Greenblatt) % -194.46
HCM's ROC (Joel Greenblatt) % is ranked lower than
97% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. HCM: -194.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HCM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -471.68  Med: -17.31 Max: 193.62
Current: -194.46
-471.68
193.62
3-Year Revenue Growth Rate 75.90
HCM's 3-Year Revenue Growth Rate is ranked higher than
97% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. HCM: 75.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HCM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -41.8  Med: 24.5 Max: 100.1
Current: 75.9
-41.8
100.1
3-Year EPS without NRI Growth Rate 23.60
HCM's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. HCM: 23.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HCM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -10  Med: 17.85 Max: 30.1
Current: 23.6
-10
30.1
GuruFocus has detected 3 Warning Signs with Hutchison China Meditech Ltd $HCM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HCM's 10-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with HCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:OTCPK:TGRNF, OTCPK:GWPRF, OTCPK:HAWPF, OTCPK:MAYNF, NAS:AERI, OTCPK:VRBCF, AMEX:TXMD, OTCPK:ABSCF, OTCPK:AIHLF, NAS:RTRX, NAS:NBRV, NAS:RMTI, NAS:ZGNX, OTCPK:DKNMF, NAS:ALIM, NAS:OASM, AMEX:NNVC, OTCPK:PXSLY, NAS:PRPH, AMEX:AXN » details
Traded in other countries:H7T.Germany, HCM.UK, HNCMF.USA,
Headquarter Location:Hong Kong
Hutchison China Meditech Ltd is a biopharmaceutical company. The Company along with its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.

Hutchison China Meditech Ltd is a major drug manufacturing company. The company operates two platforms--an innovation platform and a commercial platform. Hutchison's innovation platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases. The company's commercial platform includes the manufacturing, marketing, and distribution of prescription and over-the-counter pharmaceuticals in China as well as certain consumer products in Hong Kong. The vast majority of the company's revenue is generated through its commercial platform.

Top Ranked Articles about Hutchison China Meditech Ltd

Hutchison China Meditech Limited: Chi-Med to Announce 2016 HY Financial Results

HONG KONG, CHINA--(Marketwired - Jul 5, 2016) -  Hutchison China MediTech Limited (AIM: HCM) (NASDAQ: HCM) Chi-Med to Announce 2016 Half-Year Financial Results London: Tuesday, July 5, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An analyst presentation will be held at 9:00 am BST (4:00 pm Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins. For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (2:00 pm BST).  Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event. NOTES TO EDITORS About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform, Hutchison MediPharma Limited, is focused on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. Its pipeline of eight novel oral compounds for cancer and inflammation is in development in North America, Europe, Australia and Greater China.  Chi-Med's Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com


Contacts
 
 
 
 


 
 
 
 
 


Investor Enquiries
 
 
 
 


Christian Hogg, CEO
 
852 2121 8200
 
 


International Media Enquiries
 
 
 
 


Anthony Carlisle, Citigate Dewe Rogerson
 
44 7973 611 888 (Mobile)
 
[email protected]


U.S. Based Media Enquiries
 
 
 
 


Brad Miles, BMC Communications
 
1 (917) 570 7340 (Mobile)
 
[email protected]


Susan Duffy, BMC Communications
 
1 (917) 499 8887 (Mobile)
 
[email protected]


Investor Relations
 
 
 
 


Jillian Connell, The Trout Group
 
1 (646) 378 2956
 
[email protected]


David Dible, Citigate Dewe Rogerson
 
44 7967 566 919 (Mobile)
 
[email protected]


Panmure Gordon (UK) Limited
 
 
 
 


Richard Gray / Andrew Potts
 
44 (20) 7886 2500
 
 





Contact:

RNS

Customer Services

0044-207797-4400

[email protected]

http://www.rns.com





Read more...
Hutchison China Meditech Limited: Savolitinib Global Phase II Trial Initiated

HONG KONG, CHINA--(Marketwired - Jun 20, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) Nasdaq: HCM Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study builds on encouraging data from initial small Phase II studies of savolitinib in combination with Tagrisso or Iressa in c-Met-amplified NSCLC London: Monday, June 20, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces the initiation of a Phase II expansion of the ongoing TATTON trial (NCT02143466) to evaluate the selective c-Met inhibitor savolitinib (AZD6094) in epidermal growth factor receptor ("EGFR") mutant non-small cell lung cancer ("NSCLC") patients. Savolitinib has the potential to address major unmet medical needs in c-Met-driven subsets of NSCLC, a disease that is estimated to afflict approximately 1.7 million new patients annually worldwide. The trial is a single-arm global Phase II study of savolitinib in combination with Tagrisso (osimertinib/AZD9291) in advanced NSCLC patients who have developed resistance to approved EGFR tyrosine kinase inhibitors ("TKIs"). This expansion was initiated following encouraging early data from a number of patients enrolled in the TATTON study who received savolitinib in combination with Tagrisso. The initiation of the expanded Phase II study has triggered a US$10 million milestone payment to Hutchison MediPharma Limited ("HMP") (a 99.8% held subsidiary of Chi-Med) under the terms of the agreement with AstraZeneca PLC ("AstraZeneca") signed in December 2011. HMP and AstraZeneca are conducting Phase II studies in NSCLC with savolitinib in monotherapy, as well as in combination with either Tagrisso or Iressa (gefitinib). AstraZeneca continues to lead and invest in the global NSCLC development program for savolitinib. Susan Galbraith, Senior Vice President, Head of Oncology Innovative Medicines, AstraZeneca, said: "Savolitinib is a highly selective c-Met inhibitor that is being investigated in a number of cancers including in patients with lung cancer whose disease is driven by aberrant c-Met / HGF signaling. We are extremely excited by the data we have seen for savolitinib when used in combination with our EGFR tyrosine kinase inhibitors. We are committed to advancing research to develop a broad range of potential treatment options for patients with lung cancer." Christian Hogg, Chief Executive Officer of Chi-Med, said: "We estimate that the annual incidence of patients with MET-driven NSCLC in the U.S., European Union and Japan totals about 40,000-50,000 in all treatment settings. This is an important unmet medical need and one that we believe savolitinib is well suited to address because of its very high selectivity. This allows for effective target coverage of c-Met, as well as safe and tolerable combinations with other oncology agents. We believe that savolitinib either as a monotherapy in first-line NSCLC, or in proprietary combinations with AstraZeneca's Iressa and Tagrisso in second- and third-line NSCLC, will address the key genetic drivers of cancer cell proliferation in these very difficult-to-treat NSCLC patients. We are hopeful about proceeding into Phase III in 2017 based on future data from this study." NSCLC DEVELOPMENT PROGRAM HIGHLIGHTS

Savolitinib continues to be explored in a range of MET-driven NSCLC settings including:

- Savolitinib in combination with Tagrisso or Iressa in Phase II expansions of ongoing

 studies in advanced EGFR mutant NSCLC

- Savolitinib Tagrisso combination Phase II study in third-line NSCLC (for patients

 progressing on T790M-directed therapies)

- Savolitinib monotherapy Phase II study in NSCLC Savolitinib is in clinical development in multiple MET-driven solid tumor indications including NSCLC, kidney, gastric and colorectal cancer. For a detailed summary of all current savolitinib clinical trials covering multiple patient populations, please click here. NOTES TO EDITORS

About NSCLC and TKIs to address MET-driven and EGFR-driven NSCLC

Every year, it is estimated that approximately 1.7 million new patients around the world are diagnosed with NSCLC, according to Frost & Sullivan. Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-third of all cancer deaths, and more than breast, prostate and colorectal cancers combined. TKIs are used in many cancer therapies and act by blocking the cell signaling pathways that drive the growth of tumor cells. Around 4-5% of first-line NSCLC patients have MET-driven NSCLC, including approximately 3-4% with MET Exon-14 mutations and approximately 1-2% with c-Met gene amplification, and are generally sensitive to treatment with selective c-Met inhibitors such as savolitinib. Currently there are no approved selective c-Met TKIs for these NSCLC patients. Separately, patients who have the EGFR mutation form of NSCLC, which occurs in an estimated 10-15% of NSCLC patients in Europe and 30-40% of NSCLC patients in Asia, are particularly sensitive to treatment with currently available EGFR-TKIs. However, tumors almost always develop resistance to treatment leading to disease progression, with median progression-free periods of approximately nine months. Among NSCLC patients treated with the approved EGFR-TKIs Iressa, Tarceva (erlotinib) or Gilotrif (afatinib), who build resistance to EGFR-TKIs and thus become second-line patients, approximately half of this resistance is driven by T790M, and approximately one-fifth is driven by c-Met gene amplification. In third-line NSCLC patients treated with EGFR T790M mutation-positive TKIs, resistance pathways are only beginning to emerge as more patients are being treated with TKIs in clinical trials and Tagrisso was approved in the U.S., European Union, Japan and South Korea. Data is limited, but as patients become resistant to Tagrisso (median progression-free survival of nine months), c-Met gene amplification is emerging as a resistance pathway of significant interest. About savolitinib, a uniquely selective c-Met inhibitor

Savolitinib is a potential global first-in-class inhibitor of c-Met (also known as mesenchymal epithelial transition factor) receptor tyrosine kinase, an enzyme which has been shown to function abnormally in many types of solid tumors. It was developed as a potent and highly selective oral inhibitor specifically designed to address issues observed in the clinic with first-generation c-Met inhibitors, including renal toxicity. About Tagrisso, a selective inhibitor against EGFR and T790M mutations

Tagrisso (osimertinib) 80mg once-daily tablet, developed by AstraZeneca, is the first medicine indicated for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. Non-clinical in vitro studies have demonstrated that osimertinib has high potency and inhibitory activity against mutant EGFR phosphorylation across the range of clinically relevant EGFRm and T790M mutant NSCLC cell lines, with significantly less activity against EGFR in wild-type cell lines. Tagrisso is being compared with platinum-based doublet chemotherapy in the confirmatory AURA3 Phase III study in patients with EGFR T790M-positive, locally advanced or metastatic NSCLC who have progressed after EGFR-TKI therapy. It is also being investigated in the adjuvant and metastatic first-line settings, including in patients with and without brain metastases, in leptomeningeal disease, and in combination treatment. About Iressa, an EGFR mutation inhibitor

Iressa (gefitinib) is a targeted monotherapy developed by AstraZeneca for the treatment of patients with advanced or metastatic EGFR mutation-positive NSCLC. Iressa acts by inhibiting the tyrosine kinase enzyme in the EGFR, thus blocking the transmission of signals involved in the growth and spread of tumors. EGFR mutations occur in approximately 10-15% of NSCLC Caucasian patients and 30-40% of NSCLC patients in Asia. Iressa is approved in 91 countries worldwide. About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform, Hutchison MediPharma Limited, is focused on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. Its pipeline of eight novel oral compounds for cancer and inflammation is in development in North America, Europe, Australia and Greater China. Chi-Med's Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com. About AstraZeneca in Oncology

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients' lives and the Company's future. With at least six new medicines to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca's six Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in hematology. By harnessing the power of four scientific platforms - immuno-oncology, the genetic drivers of cancer and resistance, DNA damage response and antibody drug conjugates - and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death. About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com. Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Chi-Med's current expectations regarding future events, including its expectations for the clinical development of savolitinib, plans to initiate clinical studies for savolitinib in solid tumor indications, its expectations as to whether such studies would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates, timing and availability of subjects meeting a study's inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of a drug candidate to meet the primary or secondary endpoint of a study, the ability of a drug candidate to obtain regulatory approval in different jurisdictions, the ability of a drug candidate to gain commercial acceptance after obtaining regulatory approval, the potential market of a drug candidate for a targeted indication and the sufficiency of funding. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise. CONTACTS Chi-Med


Investor Enquiries
 
 
 
 


Christian Hogg, CEO
 
852 2121 8200
 
 


 
 
 
 
 


International Media Enquiries
 
 
 
 


Anthony Carlisle, Citigate Dewe Rogerson
 
44 7973 611 888 (Mobile)
 
[email protected]


 
 
 
 
 


U.S. Based Media Enquiries
 
 
 
 


Brad Miles, BMC Communications
 
1 (917) 570 7340 (Mobile)
 
[email protected]


Susan Duffy, BMC Communications
 
1 (917) 499 8887 (Mobile)
 
[email protected]


 
 
 
 
 


Investor Relations
 
 
 
 


Jillian Connell, The Trout Group
 
1 (646) 378 2956
 
[email protected]


David Dible, Citigate Dewe Rogerson
 
44 7967 566 919 (Mobile)
 
[email protected]


 
 
 
 
 


Panmure Gordon (UK) Limited
 
 
 
 


Richard Gray / Andrew Potts
 
44 (20) 7886 2500
 
 





Contacts:

RNS

Customer

Services

0044-207797-4400

[email protected]

http://www.rns.com





Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio No Debt
HCM's Forward PE Ratio is ranked lower than
99% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. HCM: No Debt )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 12.86
HCM's PB Ratio is ranked lower than
92% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. HCM: 12.86 )
Ranked among companies with meaningful PB Ratio only.
HCM' s PB Ratio Range Over the Past 10 Years
Min: 8.65  Med: 17.56 Max: 41.93
Current: 12.86
8.65
41.93
PS Ratio 54.48
HCM's PS Ratio is ranked lower than
99.99% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. HCM: 54.48 )
Ranked among companies with meaningful PS Ratio only.
HCM' s PS Ratio Range Over the Past 10 Years
Min: 9.38  Med: 15.34 Max: 56.67
Current: 54.48
9.38
56.67
Price-to-Free-Cash-Flow 401.04
HCM's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. HCM: 401.04 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HCM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 269.87  Med: 291.67 Max: 417.05
Current: 401.04
269.87
417.05
Price-to-Operating-Cash-Flow 372.40
HCM's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. HCM: 372.40 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HCM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 250.6  Med: 270.83 Max: 387.26
Current: 372.4
250.6
387.26
EV-to-EBIT -138.47
HCM's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. HCM: -138.47 )
Ranked among companies with meaningful EV-to-EBIT only.
HCM' s EV-to-EBIT Range Over the Past 10 Years
Min: -269.7  Med: -76.4 Max: -39
Current: -138.47
-269.7
-39
EV-to-EBITDA -155.94
HCM's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. HCM: -155.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
HCM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -346.1  Med: -83.6 Max: -40.1
Current: -155.94
-346.1
-40.1
Current Ratio 1.76
HCM's Current Ratio is ranked lower than
66% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. HCM: 1.76 )
Ranked among companies with meaningful Current Ratio only.
HCM' s Current Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.59 Max: 4.28
Current: 1.76
0.33
4.28
Quick Ratio 1.62
HCM's Quick Ratio is ranked lower than
57% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. HCM: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
HCM' s Quick Ratio Range Over the Past 10 Years
Min: 0.23  Med: 1.24 Max: 3.87
Current: 1.62
0.23
3.87
Days Inventory 28.40
HCM's Days Inventory is ranked lower than
100% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. HCM: 28.40 )
Ranked among companies with meaningful Days Inventory only.
HCM' s Days Inventory Range Over the Past 10 Years
Min: 17.86  Med: 127.27 Max: 448.99
Current: 28.4
17.86
448.99
Days Sales Outstanding 90.70
HCM's Days Sales Outstanding is ranked lower than
99.99% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. HCM: 90.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
HCM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.75  Med: 68.62 Max: 155.16
Current: 90.7
26.75
155.16
Days Payable 103.78
HCM's Days Payable is ranked lower than
96% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. HCM: 103.78 )
Ranked among companies with meaningful Days Payable only.
HCM' s Days Payable Range Over the Past 10 Years
Min: 53.45  Med: 69.98 Max: 103.78
Current: 103.78
53.45
103.78

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.30
HCM's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. HCM: -5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HCM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.8  Med: -0.5 Max: 0
Current: -5.3
-11.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 278.14
HCM's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 443 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. HCM: 278.14 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HCM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.87  Med: 7.69 Max: 284.29
Current: 278.14
0.87
284.29
Price-to-Tangible-Book 13.16
HCM's Price-to-Tangible-Book is ranked lower than
88% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. HCM: 13.16 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HCM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.45  Med: 5.99 Max: 33.29
Current: 13.16
0.45
33.29
Price-to-Intrinsic-Value-Projected-FCF 72.11
HCM's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. HCM: 72.11 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HCM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 32.67  Med: 32.67 Max: 73.7
Current: 72.11
32.67
73.7
Price-to-Median-PS-Value 3.55
HCM's Price-to-Median-PS-Value is ranked lower than
99.99% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. HCM: 3.55 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HCM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 1.01 Max: 3.63
Current: 3.55
0.12
3.63
Earnings Yield (Greenblatt) % -0.71
HCM's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. HCM: -0.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HCM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -61.79  Med: 29.2 Max: 30.6
Current: -0.71
-61.79
30.6

More Statistics

Revenue (TTM) (Mil) $197.4
EPS (TTM) $ -0.22
Short Percentage of Float0.03%
52-Week Range $9.80 - 21.77
Shares Outstanding (Mil)121.41

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 217 299 358
EPS ($) 0.00 -0.24 0.43
EPS without NRI ($) 0.00 -0.24 0.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for HCM

Headlines

Articles On GuruFocus.com
Hutchison China Meditech Limited: Chi-Med to Announce 2016 HY Financial Results Jul 05 2016 
Hutchison China Meditech Limited: Savolitinib Global Phase II Trial Initiated Jun 20 2016 

More From Other Websites
Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for... Apr 07 2017
Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors Mar 24 2017
Chi-Med To Host R&D Briefings on March 29 & 30, 2017 Mar 21 2017
Hutchison China MediTech Ltd. :HCM-US: Earnings Analysis: For the six months ended December 31, 2016... Mar 17 2017
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual... Mar 16 2017
Chi-Med: Grant of Awards under Long Term Incentive Plan Mar 16 2017
Publication of Annual Report and Financial Results for the Year Ended December 31, 2016 Mar 15 2017
Hutchison China Meditech Limited: Sulfatinib Phase Ib/II Results Presented at ENETS Mar 10 2017
Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference... Mar 10 2017
Billionaire Li's Biotech Firm a Step Closer to Putting New Cancer Drug on Market Mar 03 2017
Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of... Mar 03 2017
Hutchison China Meditech Limited: Positive Fruquintinib Pivotal Phase III Results Mar 03 2017
Hutchison China Meditech Limited: Change of Directors Feb 28 2017
Chi Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee Feb 28 2017
Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma Feb 20 2017
Hutchison China Meditech Limited: Start of Phase II Savolitinib PSC trial in China Feb 20 2017
Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017... Feb 14 2017
Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia Feb 14 2017
Hutchison China Meditech Limited: Initiates Phase I of Novel FGFR Inhibitor HMPL-453 Feb 14 2017
Hutchison China Meditech Limited: Savolitinib PRCC Results Presentation at ASCO GU Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)